Open AccessRhoGDI2 confers resistance to 5-fluorouracil in human gastric cancer cells
Author(s) -
Zhong Zheng,
Xuan He,
Jianfang Li,
Beiqin Yu,
Xuehua Chen,
Jun Ji,
Jia-Nian Zhang,
Qinxuan Gu,
Zhenggang Zhu,
Bingya Liu
Publication year - 2012
Publication title -
oncology letters
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.766
H-Index - 54
eISSN - 1792-1082
pISSN - 1792-1074
DOI - 10.3892/ol.2012.949
Subject(s) - oncogene , cancer , molecular medicine , cell cycle , cancer research , cancer cell , chemotherapy , medicine , ectopic expression , population , oncology , biology , cell culture , genetics , environmental health
Resistance to 5-fluorouracil (5-FU) in patients with gastric cancer is a serious therapeutic problem and major efforts are underway to understand the underlying mechanisms. We have previously identified RhoGDI2 as a contributor to 5-FU resistance in colon cancer cells using 2D electrophoresis and mass spectrometry and the current study aimed to further investigate this role. The expression of RhoGDI2 in seven gastric cancer cell lines was positively correlated with resistance to 5-FU. Lower 5-FU sensitivity of isolated tumor cells from patients with gastric cancer was also associated with higher RhoGDI2 expression. Ectopic expression of RhoGDI2 in gastric cancer cells increased the resistance to 5-FU and reverted low dose 5-FU-induced G2/M phase arrest without affecting the population of sub-G1 cells. Overall, these findings suggest that RhoGDI2 is associated with 5-FU resistance and is a potential therapeutic target for enhancing chemotherapy efficacy in gastric cancer.